期刊文献+

亚胺培南/西司他丁钠治疗重症肺炎的疗效观察 被引量:9

Efficacy Observation of Severe Pneumonia Treated by Different Doses of Imipenem and Cilastatin Sodium
在线阅读 下载PDF
导出
摘要 目的:观察亚胺培南/西司他丁钠治疗重症肺炎的临床疗效及安全评价。方法:将2008年6月-2012年12月收治90例重症肺炎患者随机分为A、B、C三组各30例,分别使用亚胺培南/西司他丁钠1000 ng静脉滴注,每8小时一次;500 mg静脉滴注,每6小时一次;500 mg静脉滴注,每8小时一次治疗,比较其临床疗效、细菌清除率和安全性。结果:A组、B组的临床疗效、细菌清除率和安全性均明显优于C组,P均<0.05;但A组、B组间无显著性差异。结论:亚胺培南/西司他丁钠对重症肺炎有良好疗效,使用方法以500 mg,静脉滴注,每6小时一次为最适宜。 Objective: To observe the efficacy and safety evaluation of severe pneumonia treated by Imipenem and Cilastatin Sodium. Method: 90 patients with severe pneumonia were randomly divided into group A, group B and group C,each group was 30 cases from Jun 2008 to Dec 2012. Group A was Imipenem and Cilastatin Sodium 1000 mg intravenously every 8 hours, Group B was treated by Imipenem and Cilastatin sodium 500 mg intravenously every 6 hours, Group C was treated by Imipenem and Cilastatin sodium 500 mg intravenously every 8 hours.The clinical efficacy, the rate of bacterial clearance and safety were compared among the three groups.Results : The clinical efficacy, the rate of bacterial clearance and safety in the group A and the group B were significantly better than those in the group C, all P〈0.05. But there were no difference between the group A and the group B. Conclusion:It has a good effect of severe pneumonia treated by Imipenem and Cilastatin Sodium and the best using method is 500mg intravenously every 6 hours.
出处 《岭南急诊医学杂志》 2013年第2期96-97,共2页 Lingnan Journal of Emergency Medicine
关键词 亚胺培南 西司他丁钠 重症肺炎 疗效 Imipenem and Cilastatin Sodium severe pneumonia efficacy
  • 相关文献

参考文献4

二级参考文献29

共引文献3521

同被引文献55

  • 1刘晓芹.泰能治疗下呼吸道感染50例临床体会[J].实用全科医学,2004,2(5):418-418. 被引量:2
  • 2中华人民共和国卫生部,国家中医药管理局,解放军总后勤部卫生部.关于施行《抗菌药物临床应用指导原则》的通知[J].中华医学杂志,2004,84(22):1857-1857. 被引量:109
  • 3Loan HT,Parry J, Nga NT, et al. Semi -recumbent body position fails to prevent heahhcare-associated pneumonia in Vietnamese patients with severe tetanus[J]. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2012,106(2) : 90-97.
  • 4Kim JW,Chung J,Choi SH,et al. Early use of imipenem/ cilastatin and vancomycin followed by de-escalation ver- sus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU :A randomized clinical trial[J]. Crit Care,2012,16( 1 ) : R28.
  • 5Chaulagain BP,Jang SJ,Ahn GY,et al. Molecular epi- demiology of an out-break of imipenem-resistant acineto- bacter baumannii carrying the ISAbal-bla(OXA-51-1ike) genes in a Korean hospital[J]. Jpn J Infect Dis,2012,65 (2) : 162-166.
  • 6Carraro G, Naso A, Montomoli E, et al. Thymosin-alpha 1 (Zadax-in) enhances the immunogenicity of an adjuvated pandemic H1N1 influenza vaccine (Focetria) in hemodia- lyzed patients:A pilot study[J]. Vaccine,2012,30~6) : 1170- 1180.
  • 7Morton B, Pennington SH, Gordon SB. Immunomodulatory adjuvant therapy in severe community-acquired pneumo- nia[J]. Expert Review of Respiratory Medicine,2014,8 (5) :587-596.
  • 8Wang X,Li W,Niu C,et al. Thymosin alpha 1 is associ- ated with improved cellular immunity and reduced infec- tion rate in severe acute pancreatitis patients in a dou- ble-blind randomized control study[J]. Intlammation,2011, 34(3) : 198-202.
  • 9Yang X,Qian F,He HY,et al. Effect of thymosin alpha- 1 on subpopulations of Thl,Th2,Thl7,and regulatory T cells (Tregs) in vitro[J]. Brazilian Journal of Medical and Biological Research, 2012,45 (1) : 25-32.
  • 10赵丽丽,张瑶,张虹.亚胺培南/西司他丁对重症肺炎的降阶梯治疗疗效分析[J].中国药物经济学,2014,9(10):219-220.

引证文献9

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部